EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial

Akari Hiraku, Setsuko Nakata, Mai Murata, Chendong Xu, Natsumi Mutoh, Satoshi Arai, Toshitaka Odamaki iD, Noriyuki Iwabuchi, Miyuki Tanaka, Takahisa Tsuno, Masahiko Nakamura

Nutrients · 14.03.2023 · 15 (6) · 1402

DOI: 10.3390/nu15061402 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 14.03.2023. Verfasst von Akari Hiraku und 10 weiteren Autor:innen. Beteiligte Einrichtung: Food Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Morinaga Milk Industry, Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of Bifidobacterium longum subsp. infantis (B. infantis) M-63 in healthy infants in a double-blind, randomized, placebo-controlled trial. Healthy term infants were given B. infantis M-63 (n = 56; 1 × 109 CFU/day) or placebo (n = 54) from postnatal age ≤ 7 days to 3 months. Fecal samples were collected, and fecal microbiota, stool pH, short-chain fatty acids, and immune substances were analyzed. Supplementation with B. infantis M-63 significantly increased the relative abundance of Bifidobacterium compared with the placebo group, with a positive correlation with the frequency of breastfeeding. Supplementation with B. infantis M-63 led to decreased stool pH and increased levels of acetic acid and IgA in the stool at 1 month of age compared with the placebo group. There was a decreased frequency of defecation and watery stools in the probiotic group. No adverse events related to test foods were observed. These results indicate that early supplementation with B. infantis M-63 is well tolerated and contributes to the development of Bifidobacterium-predominant gut microbiota during a critical developmental phase in term infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeProbioticsFemaleHumansInfantInfant, NewbornBifidobacteriumBifidobacterium longum subspecies infantisBreast FeedingFeces

Stichwörter der Autor:innen

Bifidobacterium longum subsp. InfantisGI motilitygut microbiotaprobioticssecretory IgAshort-chain fatty acidsterm infant

Autor:innen und Institutionen

  • Food Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan.
  • Department of Pediatrics, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, Japan.
  • Next Generation Science Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan.
  • Department of neurosurgery, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, Japan.

ORCID-Profile: Toshitaka Odamaki

Förderung

  • Morinaga Milk Industry, Co., Ltd.

Zitieren

APA

Hiraku, A., Nakata, S., Murata, M., Xu, C., Mutoh, N., Arai, S., Odamaki, T., Iwabuchi, N., Tanaka, M., Tsuno, T., & Nakamura, M. (2023). Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial. Nutrients, 15(6), 1402. https://doi.org/10.3390/nu15061402

Vancouver

Hiraku A, Nakata S, Murata M, Xu C, Mutoh N, Arai S, et al. Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial. Nutrients. 2023;15(6):1402. doi:10.3390/nu15061402

BibTeX
@article{Hiraku2023,
  author = {Hiraku, Akari and Nakata, Setsuko and Murata, Mai and Xu, Chendong and Mutoh, Natsumi and Arai, Satoshi and Odamaki, Toshitaka and Iwabuchi, Noriyuki and Tanaka, Miyuki and Tsuno, Takahisa and Nakamura, Masahiko},
  title = {Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial},
  journal = {Nutrients},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1402},
  doi = {10.3390/nu15061402}
}
Kostenlos starten →